Characteristics and prognosis of pelvic Ewing sarcoma: a SEER population-based study

Chen, Li; Cheng, Long; Liu, Jiaxin; Xing, Fei; Duan, Xin

doi:10.7717/peerj.7710

Cited by 29 publications

(38 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we apply subgroup analysis to demonstrate effect of surgical therapy on patient outcome among different extend of disease, surgery margin and chemotherapeutic respond. Surgical patients are reported advantage in surviving comparing to nonsurgical LC approaches based on population research (25,26). Our study reveals that patients with surgical therapy have higher PFS and LC than nonsurgical patients (PFS: RR 0.72, 95% CI: 0.61-0.86, P<0.001; LC: RR 0.72, 95% CI: 0.52-1.00, P=0.05).…”

Section: Discussionmentioning

confidence: 66%

Comparison of local control and survival outcomes between surgical and non-surgical local therapy on pelvic Ewing’s sarcoma patients: a meta-analysis

Xie¹,

Zeng²,

Yao³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: The efficacy of surgical therapy to nonsurgical therapy is still a controversial topic in pelvic Ewing's sarcoma (ES) management. We perform a systemic review and meta-analysis to compare the effect of local control (LC) and survival outcomes between surgical and nonsurgical local therapy on pelvic ES patients with systemic chemotherapy.Methods: Published retrospective studies searched from PubMed, Embase, Cochrane and Web of Science databases that investigated the effects of surgical and nonsurgical local therapy on the LC and survival outcomes of patients with pelvic ES treated with chemotherapy were included in our study. Our primary outcome was the LC rate and progression-free survival (PFS) rate. The effect of confounders of extend of disease, surgical margin and chemotherapy respond on PFS was analyzed in subgroups.Results: Ten studies with 782 pelvic ES patients were included in our analysis. Surgical patients showed higher LC and PFS rate comparing to nonsurgical patients [LC: risk ratio (RR) 0.72, 95% CI: 0.52-1.00, P=0.05, I 2 =0%; PFS: RR 0.72, 95% CI: 0.61-0.86, P=0.000, I 2 =15%]. Localized patients showed higher PFS with surgical therapy than nonsurgical patients (RR 0.67, 95% CI: 0.51-0.88, P=0.003).Patients with adequate resection and good chemotherapy respond improved PFS comparing to nonsurgical patients (adequate resection vs. nonsurgical: RR 0.59, 95% CI: 0.46-0.76, P<0.001, I 2 =0%; good respond vs. nonsurgical: RR 0.56, 95% CI: 0.41-0.77, P<0.001, I 2 =21%). But patients with inadequate resection and poor chemotherapeutic respond shows no statistical different PFS comparing to nonsurgical patients (inadequate

show abstract

Section: Discussionmentioning

confidence: 66%

Comparison of local control and survival outcomes between surgical and non-surgical local therapy on pelvic Ewing’s sarcoma patients: a meta-analysis

Xie¹,

Zeng²,

Yao³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Recently, surgery has been increasingly preferred to treat pelvic ES [4]. Chen et al [5] also reported that surgical treatments are associated with better outcomes for pelvic ES. Several previous studies have compared radiotherapy to surgery, and reported surgery to be superior in terms of event-free survival, overall survival, and local control [6, 7].…”

Section: Discussionmentioning

confidence: 99%

Reconstruction after Subtotal Sacrectomy for Sacral Ewing’s Sarcoma Using Tibial Allograft Strut Grafting: A Case Report

Hirota¹,

Emori²,

Terashima³

et al. 2021

Case Rep Oncol

View full text Add to dashboard Cite

We present the case of a 15-year-old girl. Two months after becoming aware of pain, she was diagnosed with a sacral tumor and referred to our department. She was diagnosed with a sacral Ewing’s sarcoma; after chemotherapy, it was determined that the tumor could be resected, so surgical treatment was performed. The sacrum and ilium were partially resected at the lower end of S1, and the lumbar vertebrae and pelvis were fixed with a pedicle screw and two iliac screws on each side of L3, and the sacral resection was reconstructed with a tibial strut allograft. No tumor recurrence or metastasis has been observed 1 year postoperatively. She developed bladder and rectal dysfunction, but she remained independent in activities of daily living and her daily life was not limited. The bone fusion in the reconstructed area confirmed the lack of instrumentation looseness. Surgical treatment for sacral Ewing’s sarcoma was performed to cure the patient. We believe that the tibial allograft contributed to the patient’s ability to walk on her own due to its high mechanical stability. Postoperative bone healing was observed with the same material, suggesting that the tibial allograft is useful for similar procedures.

show abstract

“…In addition, we also found that large tumor size was an independent predictor for the presentation of lung metastasis in ES patients at initial diagnosis. Large tumor size has been consistently reported as a contributor to the poor prognosis of ES patients [ 7 , 15 , 28 , 29 ], and it also has a major influence on metastasis in ES. Hense et al identified that increased tumor size was positively associated with metastasis in patients with ES [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Lung Metastasis Probability in Ewing Sarcoma: A Nomogram Based on the SEER Database

2020

View full text Add to dashboard Cite

Background. Up to now, an accurate nomogram to predict the lung metastasis probability in Ewing sarcoma (ES) at initial diagnosis is lacking. Our objective was to construct and validate a nomogram for the prediction of lung metastasis in ES patients. Methods. A total of 1157 patients with ES from the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively collected. The predictors of lung metastasis were identified via the least absolute shrinkage and selection operator (LASSO) and multivariate logistic analysis. The discrimination and calibration of the nomogram were validated by receiver operating characteristic (ROC) curve and calibration curve. Decision curve analysis (DCA) was used to evaluate the clinical usefulness and net benefits of the prediction model. Results. Factors including age, tumor size, primary site, tumor extension, and other site metastasis were identified as the ultimate predictors for the nomogram. The calibration curves for the training and validation cohorts both revealed good agreement, and the Hosmer–Lemeshow test identified that the model was well fitted (p > 0.05). In addition, the area under the ROC curve (AUC) values in the training and validation cohorts were 0.732 (95% confidence interval, CI: 0.607–0.808) and 0.741 (95% CI: 0.602–0.856), respectively, indicating good predictive discrimination. The DCA showed that when the predictive metastasis probability was between 1% and 90%, the nomogram could provide clinical usefulness and net benefit. Conclusion. The nomogram constructed and validated by us could provide a convenient and effective tool for clinicians that can improve prediction of the probability of lung metastasis in patients with ES at initial diagnosis.

show abstract

Characteristics and prognosis of pelvic Ewing sarcoma: a SEER population-based study

Cited by 29 publications

References 38 publications

Comparison of local control and survival outcomes between surgical and non-surgical local therapy on pelvic Ewing’s sarcoma patients: a meta-analysis

Comparison of local control and survival outcomes between surgical and non-surgical local therapy on pelvic Ewing’s sarcoma patients: a meta-analysis

Reconstruction after Subtotal Sacrectomy for Sacral Ewing’s Sarcoma Using Tibial Allograft Strut Grafting: A Case Report

Lung Metastasis Probability in Ewing Sarcoma: A Nomogram Based on the SEER Database

Contact Info

Product

Resources

About